Glaukos (NYSE:GKOS) Stock Lifted to “Strong-Buy” by Zacks Research

Zacks Research upgraded shares of Glaukos (NYSE:GKOS) from a hold rating to a strong-buy rating in a research note issued to investors on Wednesday,Zacks reports.

A number of other brokerages have also issued reports on GKOS. Piper Sandler reiterated an “overweight” rating and set a $240.00 price target (up from $195.00) on shares of Glaukos in a research note on Thursday. Stifel Nicolaus raised their price objective on shares of Glaukos from $190.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday. Truist Financial raised their price objective on shares of Glaukos from $215.00 to $255.00 and gave the company a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. lifted their price objective on shares of Glaukos from $200.00 to $240.00 and gave the company an “overweight” rating in a report on Thursday. Finally, BTIG Research upped their target price on shares of Glaukos from $205.00 to $234.00 and gave the stock a “buy” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $216.71.

Glaukos Trading Up 32.7%

GKOS opened at $240.81 on Wednesday. Glaukos has a 52 week low of $80.90 and a 52 week high of $243.71. The business has a fifty day simple moving average of $172.26 and a 200-day simple moving average of $140.51. The firm has a market cap of $14.20 billion, a P/E ratio of -81.91 and a beta of 0.69. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.98% and a negative net margin of 24.60%. The firm had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. During the same quarter in the previous year, the business earned ($0.16) EPS. The company’s quarterly revenue was up 58.0% compared to the same quarter last year. On average, equities analysts expect that Glaukos will post -0.32 earnings per share for the current year.

Insiders Place Their Bets

In other Glaukos news, CFO Alex Thurman sold 20,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the sale, the chief financial officer owned 43,906 shares of the company’s stock, valued at $7,908,787.78. This trade represents a 31.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 60,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the sale, the chief operating officer directly owned 72,588 shares in the company, valued at $13,046,967.12. This represents a 45.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 82,500 shares of company stock worth $14,862,000 in the last quarter. 5.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP purchased a new stake in Glaukos during the second quarter worth approximately $28,000. CoreCap Advisors LLC acquired a new position in Glaukos in the third quarter valued at approximately $33,000. Fortitude Family Office LLC purchased a new position in Glaukos in the third quarter valued at approximately $36,000. Parallel Advisors LLC increased its stake in Glaukos by 159.2% in the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares during the last quarter. Finally, IFP Advisors Inc increased its stake in Glaukos by 523.4% in the second quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 246 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Trending Headlines about Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Q3 results far exceeded expectations: Third-quarter revenue rose 58% year over year to approximately $211 million, well above the roughly $168 million analyst estimate. The company reported adjusted EPS of $0.47 versus consensus expectations for a loss of about $0.10–$0.12, compared with a $0.16 loss a year earlier. Glaukos Stock Charges Higher on Q3 Earnings Surprise
• Positive Sentiment: Profitability improved: Glaukos reported approximately $2 million in GAAP net income, or $0.03 per diluted share, marking a swing from a year-earlier loss. Operating cash flow was $14.8 million, and the company ended the quarter with $162.3 million in cash. Glaukos Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Sales outlook was raised: Management increased its 2026 revenue guidance to $775 million–$785 million from $680 million–$700 million and introduced a preliminary 2027 sales target of $1 billion. Investors viewed the outlook as evidence that iDose TR and Epioxa can sustain strong growth. Glaukos Sets $1 Billion 2027 Sales Goal
• Positive Sentiment: Analysts raised targets: JPMorgan lifted its target to $240 and retained an Overweight rating, while Needham raised its target to $251 with a Buy rating. BTIG, Stifel and Wells Fargo also increased their targets and maintained positive ratings. JPMorgan Analyst Recommendation
• Neutral Sentiment: Valuation has become demanding: The stock was trading near its 52-week high and above several newly raised analyst targets, including those from Wells Fargo, BTIG and Stifel, potentially limiting near-term upside despite bullish ratings.
• Negative Sentiment: Insider selling remains a risk signal: Data provided shows 32 open-market insider sales and no purchases over the past six months. The company also remains dependent on continued execution to meet its ambitious 2027 target.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.